Category Archives: Healthcare

Prevail Therapeutics (PRVL) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Prevail Therapeutics (PRVL – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $13.55. According to TipRanks.com, Olson ‘s ranking

Alpine Immune Sciences (ALPN) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN – Research Report) yesterday and set a price target of $19.00. The company’s shares closed last Tuesday at $10.19. According to TipRanks.com, Breidenbach is a 5-star analyst

Motus Gi Holdings (MOTS) Receives a Buy from Oppenheimer

In a report released yesterday, Steven Lichtman from Oppenheimer maintained a Buy rating on Motus Gi Holdings (MOTS – Research Report), with a price target of $2.50. The company’s shares closed last Tuesday at $1.19. According to TipRanks.com, Lichtman is

Oppenheimer Sticks to Their Hold Rating for Sunesis Pharma (SNSS)

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sunesis Pharma (SNSS – Research Report) yesterday. The company’s shares closed last Tuesday at $0.33, close to its 52-week low of $0.20. According to TipRanks.com, Singh is a 5-star analyst with

Intercept Pharma (ICPT) Gets a Hold Rating from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Intercept Pharma (ICPT – Research Report) on August 10 and set a price target of $57.00. The company’s shares closed last Tuesday at $52.58, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and AnaptysBio (NASDAQ: ANAB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SAGE Therapeutics (SAGE – Research Report) and AnaptysBio (ANAB – Research Report). SAGE Therapeutics (SAGE) In a report issued on August 10, Brian